N. AKYÜREK Et Al. , "Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab," CANCER , vol.118, no.17, pp.4173-4183, 2012
AKYÜREK, N. Et Al. 2012. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. CANCER , vol.118, no.17 , 4173-4183.
AKYÜREK, N., ÜNER, A., Benekli, M., & BARIŞTA, İ., (2012). Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. CANCER , vol.118, no.17, 4173-4183.
AKYÜREK, NALAN Et Al. "Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab," CANCER , vol.118, no.17, 4173-4183, 2012
AKYÜREK, NALAN Et Al. "Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab." CANCER , vol.118, no.17, pp.4173-4183, 2012
AKYÜREK, N. Et Al. (2012) . "Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab." CANCER , vol.118, no.17, pp.4173-4183.
@article{article, author={NALAN AKYÜREK Et Al. }, title={Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab}, journal={CANCER}, year=2012, pages={4173-4183} }